Logo image of IMTX

IMMATICS NV (IMTX) Stock Fundamental Analysis

USA - NASDAQ:IMTX - NL0015285941 - Common Stock

9.4 USD
+0.67 (+7.67%)
Last: 10/3/2025, 8:00:02 PM
9.4 USD
0 (0%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

3

Overall IMTX gets a fundamental rating of 3 out of 10. We evaluated IMTX against 536 industry peers in the Biotechnology industry. The financial health of IMTX is average, but there are quite some concerns on its profitability. IMTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMTX had negative earnings in the past year.
IMTX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: IMTX reported negative net income in multiple years.
In multiple years IMTX reported negative operating cash flow during the last 5 years.
IMTX Yearly Net Income VS EBIT VS OCF VS FCFIMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -13.03%, IMTX belongs to the top of the industry, outperforming 82.65% of the companies in the same industry.
IMTX's Return On Equity of -15.91% is amongst the best of the industry. IMTX outperforms 86.94% of its industry peers.
Industry RankSector Rank
ROA -13.03%
ROE -15.91%
ROIC N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
IMTX Yearly ROA, ROE, ROICIMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMTX Yearly Profit, Operating, Gross MarginsIMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

IMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMTX has been increased compared to 1 year ago.
IMTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IMTX has an improved debt to assets ratio.
IMTX Yearly Shares OutstandingIMTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMTX Yearly Total Debt VS Total AssetsIMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.61 indicates that IMTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.61, IMTX is in the better half of the industry, outperforming 74.25% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that IMTX is not too dependend on debt financing.
IMTX's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. IMTX outperforms 41.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.61
ROIC/WACCN/A
WACC7.27%
IMTX Yearly LT Debt VS Equity VS FCFIMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

IMTX has a Current Ratio of 8.80. This indicates that IMTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IMTX (8.80) is better than 76.87% of its industry peers.
A Quick Ratio of 8.80 indicates that IMTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.80, IMTX is doing good in the industry, outperforming 77.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.8
Quick Ratio 8.8
IMTX Yearly Current Assets VS Current LiabilitesIMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

IMTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.71%, which is quite impressive.
The Revenue has grown by 83.62% in the past year. This is a very strong growth!
IMTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 53.31% yearly.
EPS 1Y (TTM)31.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.18%
Revenue 1Y (TTM)83.62%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-74.74%

3.2 Future

The Earnings Per Share is expected to decrease by -53.40% on average over the next years. This is quite bad
The Revenue is expected to grow by 13.23% on average over the next years. This is quite good.
EPS Next Y-1146.06%
EPS Next 2Y-249.53%
EPS Next 3Y-128.99%
EPS Next 5Y-53.4%
Revenue Next Year-57.52%
Revenue Next 2Y-34.68%
Revenue Next 3Y-9.45%
Revenue Next 5Y13.23%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IMTX Yearly Revenue VS EstimatesIMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
IMTX Yearly EPS VS EstimatesIMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMTX Price Earnings VS Forward Price EarningsIMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMTX Per share dataIMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

IMTX's earnings are expected to decrease with -128.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-249.53%
EPS Next 3Y-128.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMATICS NV

NASDAQ:IMTX (10/3/2025, 8:00:02 PM)

After market: 9.4 0 (0%)

9.4

+0.67 (+7.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-17 2025-11-17
Inst Owners71.25%
Inst Owner Change0%
Ins Owners4.66%
Ins Owner ChangeN/A
Market Cap1.14B
Analysts88
Price Target14.41 (53.3%)
Short Float %4.28%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-38.62%
Min EPS beat(2)-77.7%
Max EPS beat(2)0.45%
EPS beat(4)3
Avg EPS beat(4)54.7%
Min EPS beat(4)-77.7%
Max EPS beat(4)226.79%
EPS beat(8)7
Avg EPS beat(8)46.07%
EPS beat(12)9
Avg EPS beat(12)28.53%
EPS beat(16)9
Avg EPS beat(16)0.45%
Revenue beat(2)1
Avg Revenue beat(2)-17.93%
Min Revenue beat(2)-66.37%
Max Revenue beat(2)30.5%
Revenue beat(4)3
Avg Revenue beat(4)109.11%
Min Revenue beat(4)-66.37%
Max Revenue beat(4)264.77%
Revenue beat(8)6
Avg Revenue beat(8)59.11%
Revenue beat(12)9
Avg Revenue beat(12)46.5%
Revenue beat(16)9
Avg Revenue beat(16)24.24%
PT rev (1m)1.93%
PT rev (3m)-2.1%
EPS NQ rev (1m)2.57%
EPS NQ rev (3m)-15.88%
EPS NY rev (1m)-3.34%
EPS NY rev (3m)-22.41%
Revenue NQ rev (1m)-3.67%
Revenue NQ rev (3m)-14.56%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-22.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.48
P/FCF N/A
P/OCF N/A
P/B 2.1
P/tB 2.1
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS1.26
BVpS4.48
TBVpS4.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.03%
ROE -15.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.18%
Cap/Sales 7.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.8
Quick Ratio 8.8
Altman-Z 4.61
F-Score3
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)217.11%
Cap/Depr(5y)185.86%
Cap/Sales(3y)23.83%
Cap/Sales(5y)22.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.18%
EPS Next Y-1146.06%
EPS Next 2Y-249.53%
EPS Next 3Y-128.99%
EPS Next 5Y-53.4%
Revenue 1Y (TTM)83.62%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-74.74%
Revenue Next Year-57.52%
Revenue Next 2Y-34.68%
Revenue Next 3Y-9.45%
Revenue Next 5Y13.23%
EBIT growth 1Y13.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-122.7%
EBIT Next 3Y-45.75%
EBIT Next 5Y-25.47%
FCF growth 1Y-65.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.4%
OCF growth 3YN/A
OCF growth 5YN/A